AB AB Science SA

AB Science announces that results from masitinib study AB07015 in severe asthma have been selected for presentation at an ATS symposium held on 16th October, 2020

AB Science announces that results from masitinib study AB07015 in severe asthma have been selected for presentation at an ATS symposium held on 16th October, 2020
EN
13/10/2020

Underlying

ABAB Science SA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on AB Science SA

 PRESS RELEASE
Free
AB AB SCIENCE SA

AB Science announced that the Food and Drug Administration (FDA) grant...

AB Science announced that the Food and Drug Administration (FDA) granted the status of Minor Use in Major Species (MUMS) for Masivet® in the treatment of canine mast cell tumors PRESS RELEASE AB SCIENCE ANNOUNCES THAT THE FDA HAS GRANTED THE STATUS OF MINOR USE IN MAJOR SPECIES DESIGNATION FOR MASIVET IN THE TREATMENT OF CANINE MAST CELL TUMORS AB SCIENCE PRESENTS PERSPECTIVE OF THE ANIMAL HEALTH FRANCHISE Paris, February 9, 2026, 6pm CET AB Science SA (Euronext - FR0010557264 - AB) announced that the Food and Drug Administration (FDA) granted the status of Minor Use in Major Species (M...

February 9, 2026 1 EN
 PRESS RELEASE
Free
AB AB SCIENCE SA

AB Science annonce que la Food and Drug Administration (FDA) américain...

AB Science annonce que la Food and Drug Administration (FDA) américaine a accordé le statut de Minor Use in Major Species (MUMS) au Masivet® dans le traitement des tumeurs mastocytaires chez le chien COMMUNIQUÉ DE PRESSE AB SCIENCE ANNONCE QUE LA FDA A ACCORDÉ LE STATUT DE “MINOR USE IN MAJOR SPECIES” (MUMS) AU MASIVET DANS LE TRAITEMENT DES TUMEURS MASTOCYTAIRES CHEZ LE CHIEN AB SCIENCE PRÉSENTE LES PERSPECTIVES DE SA FRANCHISE ANIMALE Paris, le 9 février 2026, 18h00 AB Science SA (Euronext - FR0010557264 - AB) annonce que la Food and Drug Administration (FDA) américaine a accordé le s...

February 9, 2026 1 EN
 PRESS RELEASE
Free
AB AB SCIENCE SA

AB Science receives notice of allowance for US patent covering masitin...

AB Science receives notice of allowance for US patent covering masitinib in the treatment of metastatic castrate resistant prostate cancer PRESS RELEASE AB SCIENCE RECEIVES NOTICE OF ALLOWANCE FOR UNITED STATES PATENT COVERING MASITINIB IN THE TREATMENT OF METASTATIC CASTRATE RESISTANT PROSTATE CANCER THIS POSITIVE DECISION FROM THE USA PATENT OFFICE STRENGTHENS THE COMPANY’S INTELLECTUAL PROPERTY POSITION IN THIS INDICATION UNTIL 2042, ADDING TO THE COVERAGE ALREADY GRANTED IN EUROPE Paris, January 29, 2026, 6pm CET AB Science SA (Euronext - FR0010557264 - AB) announced that the Unite...

January 29, 2026 1 EN
 PRESS RELEASE
Free
AB AB SCIENCE SA

AB Science reçoit un avis d'autorisation pour un brevet américain couv...

AB Science reçoit un avis d'autorisation pour un brevet américain couvrant le masitinib dans le traitement du cancer de la prostate métastatique hormono-resistant COMMUNIQUÉ DE PRESSE AB SCIENCE REÇOIT UN AVIS D'AUTORISATION POUR UN BREVET AMÉRICAIN COUVRANT LE MASITINIB DANS LE TRAITEMENT DU CANCER DE LA PROSTATE MÉTASTATIQUE HORMONO-RESISTANT CETTE DÉCISION FAVORABLE DE L’OFFICE AMERICAIN DES BREVETS RENFORCE LA POSITION DE LA SOCIÉTÉ EN MATIÈRE DE PROPRIÉTÉ INTELLECTUELLE DANS CETTE INDICATION JUSQU'EN 2042, S'AJOUTANT À LA COUVERTURE DÉJÀ ACCORDÉE EN EUROPE Paris, le 29 janvier 2026...

January 29, 2026 1 EN
Jean-Pierre Loza
  • Jean-Pierre Loza
01/29/26 January 29, 2026 1 FR

ResearchPool Subscriptions

Get the most out of your insights

Get in touch